Cost-utility analysis of teriflunomide in naive vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.

ABSTRACT:

Background

Multiple sclerosis (MS) accounts for 176 cases per 100,000 inhabitants (female/male ratio = 2:1) in Italy. For most of the patients (67%), the disease course is relapsing-remitting MS (RRMS).

Objective

To compare the costs and quality-adjusted life years (QALYs) of teriflunomide in RRMS naïve patients vs. RRMS patients previously treated (experienced) with other disease-modifying therapies in Italy.

Methods

A four health states Markov model-supported cost-utility analysis (CUA) covering a 7-year timespan through annual cycles was developed, following the healthcare sector and the societal viewpoints. Part of the parameters that populated the Markov model was obtained from a questionnaire administered to four primary Italian MS centres. Costs of healthcare a

SUBMITTER: Lazzaro C 

PROVIDER: S-EPMC9349140 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature